These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8994774)

  • 1. Variability of plasma fluconazole levels in patients with hematologic malignancy.
    Ellis ME; Spence D; Ernst P; Greer W
    Clin Infect Dis; 1997 Jan; 24(1):86-7. PubMed ID: 8994774
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum levels of fluconazole in patients after cytotoxic chemotherapy for hematological malignancy.
    Kami M; Sawada Y; Mori S; Hirate J; Kojima N; Kanda Y; Moriya A; Yuji K; Saito T; Chiba S; Hirai H
    Am J Hematol; 2001 Feb; 66(2):85-91. PubMed ID: 11421304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.
    Debruyne D
    Clin Pharmacokinet; 1997 Jul; 33(1):52-77. PubMed ID: 9250423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Level of evidence for therapeutic drug monitoring of fluconazole].
    Venisse N; Le Guellec C
    Therapie; 2011; 66(2):97-101. PubMed ID: 21635855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacokinetics and dosage of fluconazole in continuous hemofiltration (CAVH, CVVH) and hemodialysis (CAVHD, CVVHD)].
    Pittrow L; Penk A
    Mycoses; 1998; 41 Suppl 2():86-8. PubMed ID: 10085695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluconazole.
    Jura SE; Hillenbrand K
    Pediatr Rev; 2006 Apr; 27(4):158-9. PubMed ID: 16581959
    [No Abstract]   [Full Text] [Related]  

  • 7. In meta-analysis itraconazole is superior to fluconazole for prophylaxis of systemic fungal infection in the treatment of haematological malignancy.
    Prentice AG; Glasmacher A; Djulbegovic B
    Br J Haematol; 2006 Mar; 132(5):656-8; author reply 658-9. PubMed ID: 16445845
    [No Abstract]   [Full Text] [Related]  

  • 8. Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients.
    Almyroudis NG; Segal BH
    Expert Rev Anti Infect Ther; 2010 Dec; 8(12):1451-66. PubMed ID: 21133669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of fluconazole after administration of fosfluconazole and fluconazole in critically ill patients.
    Aoyama T; Hirata K; Hirata R; Yamazaki H; Yamamoto Y; Hayashi H; Matsumoto Y
    J Clin Pharm Ther; 2012 Jun; 37(3):356-63. PubMed ID: 21883330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current Status and Future Perspectives of Primary Antifungal Prophylaxis in Patients with Hematological Malignancies-Review].
    Li Y; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):627-632. PubMed ID: 28446325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluconazole: comparison of pharmacokinetics, therapy and in vitro susceptibility.
    Wildfeuer A; Laufen H; Schmalreck AF; Yeates RA; Zimmermann T
    Mycoses; 1997 Nov; 40(7-8):259-65. PubMed ID: 9476508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapy of invasive mycoses in neutropenic patients with hematologic system diseases].
    Glasmacher A; Just-Nübling G; Molitor E
    Dtsch Med Wochenschr; 1998 Feb; 123(7):191-4. PubMed ID: 9505945
    [No Abstract]   [Full Text] [Related]  

  • 13. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature.
    Martino R; Lopez R; Sureda A; Brunet S; Domingo-Albós A
    Haematologica; 1997; 82(3):297-304. PubMed ID: 9234575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multidisciplinary approach to managing invasive fungal disease. Introduction and aims.
    Donnelly JP
    J Antimicrob Chemother; 2013 Nov; 68 Suppl 3():iii3-4. PubMed ID: 24319773
    [No Abstract]   [Full Text] [Related]  

  • 15. Population pharmacokinetic analysis of fluconazole to predict therapeutic outcome in burn patients with Candida infection.
    Han S; Kim J; Yim H; Hur J; Song W; Lee J; Jeon S; Hong T; Woo H; Yim DS
    Antimicrob Agents Chemother; 2013 Feb; 57(2):1006-11. PubMed ID: 23254425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluconazole in filamentous fungal keratitis.
    Rao SK; Madhavan HN; Rao G; Padmanabhan P
    Cornea; 1997 Nov; 16(6):700. PubMed ID: 9395885
    [No Abstract]   [Full Text] [Related]  

  • 17. [Fluconazole: comparison of pharmacokinetics, therapy and in vitro susceptibility of yeasts].
    Wildfeuer A; Laufen H; Schmalreck AF; Yeates RA; Zimmermann T
    Mycoses; 1996; 39 Suppl 2():51-7. PubMed ID: 9198746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vivo Microdialysis To Determine Subcutaneous Interstitial Fluid Penetration and Pharmacokinetics of Fluconazole in Intensive Care Unit Patients with Sepsis.
    Sinnollareddy MG; Roberts MS; Lipman J; Lassig-Smith M; Starr T; Robertson T; Peake SL; Roberts JA
    Antimicrob Agents Chemother; 2016 Feb; 60(2):827-32. PubMed ID: 26596947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-Analysis and Cost Comparison of Empirical versus Pre-Emptive Antifungal Strategies in Hematologic Malignancy Patients with High-Risk Febrile Neutropenia.
    Fung M; Kim J; Marty FM; Schwarzinger M; Koo S
    PLoS One; 2015; 10(11):e0140930. PubMed ID: 26554923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Laboratory monitoring of antifungal chemotherapy. British Society for Antimicrobial Chemotherapy Working Party.
    Lancet; 1991 Jun; 337(8757):1577-80. PubMed ID: 1675717
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.